| Type of Capital
Measure |
Date
(MM/DD/JJ) |
Gross
proceeds
(Mio. €) |
Issue
price
(€) |
Total number
of shares
after issuance |
Number of
shares
issued |
| Capital Increase against Cash |
24.05.18 |
32.3 |
14.50 |
24,544,595 |
2,230,000 |
| Capital Increase in Kind (acquisition of Trianta) |
18.09.17 |
2.0 |
10.9687 |
22,300,947 |
182,335 |
| Capital Increase against Cash |
08.05.17 |
20.7 |
10.55 |
22,118,329 |
1,964,599 |
| Termination of convertible bond program issued on July 21, 2014 |
21.07.16 |
|
|
20,136,887 |
167,164 |
| Capital Increase in Kind (acquisition of Trianta) |
20.05.16 |
3.2 |
8.08 |
20,081,835 |
392,875 |
| Capital Increase against Cash |
03.07.15 |
46.4 |
8.30 |
19,645,993 |
5,594,178 |
| Capital Increase in Kind (acquisition of Trianta) |
16.06.15 |
0.7 |
10.55 |
14,051,815 |
66,370 |
| Issuance of 818,658 convertable bonds |
21.07.14 |
0.8 |
1.00 |
|
|
| Capital Increase against Cash |
17.07.14 |
15.1 |
5.00 |
13,906,032 |
3,016,082 |
| Capital Increase in Kind (acquisition of Trianta) |
12.03.14 |
4.0 |
3.93 |
10,889,950 |
1,017,811 |
| Share capital reduction |
29.10.13 |
|
|
9,872,139 |
|
| Capital Increase against Cash |
29.05.13 |
2.4 |
1.00 |
39,488,558 |
2,405,800 |
| Capital Increase against Cash (Seda2) |
30.06.10 |
1.5 |
2.55 |
37,082,758 |
588,235 |
| Capital Increase against Cash (Seda2) |
04.05.10 |
1.0 |
2,76 |
36,494,523 |
362,318 |
| Capital Increase against Cash (Seda2) |
24.03.10 |
2.0 |
3.48 |
36,132,205 |
574,712 |
| Capital Increase against Cash (Seda2) |
11.12.09 |
2.0 |
3.52 |
35,557,493 |
568,181 |
| Capital Increase against Cash (Seda2) |
18.11.09 |
2.0 |
3.94 |
34,989,312 |
507,614 |
| Capital Increase against Cash (Seda2) |
02.11.09 |
1.0 |
4.46 |
34,481,698 |
224,215 |
| Capital Increase against Cash (Seda2) |
13.10.09 |
1.0 |
4.87 |
34,257,483 |
205,338 |
| Capital Increase against Cash |
03.06.09 |
0.1 |
4.24 |
34,052,145 |
23,584 |
| Capital Increase against Cash |
10.09.07 |
15.6 |
5.05 |
33,927,121 |
3,084,282 |
| Capital Increase against Cash |
14.02.07 |
12.6 |
6.10 |
30,842,839 |
2,062,040 |
| Acquisition of Avidex Ltd. |
27.09.06 |
50.1 |
6.00 |
28,651,070 |
8,157,787 |
| Capital Increase against Cash |
02.03.06 |
15.7 |
8.45 |
20,620,452 |
1,852,260 |
| Conversion of all outstanding bonds
issued on March 24, 2004 |
16.12.05 |
|
7.48 |
18,722,666 |
199,982 |
| Capital Increase against Cash |
15.11.04 |
21.6 |
7.00 |
18,522,684 |
3,087,114 |
| Acquisition of the Assets
of Munich Biotech AG |
13.08.04 |
11.3 |
5.76 |
15,435,170 |
1,960,938 |
| Issuance of Convertible Bonds at a Price of 1 € each |
24.03.04 |
1.5 |
1.00 |
13,474,032 |
|
| Capital Increase against Cash |
24.03.04 |
15.3 |
6.80 |
13,474,032 |
1,122,835 |
|
|
|
|
|
1,122,835 |
|
|
1.51 |
7.501 |
|
|
| Acquisition NeuroVir |
12.01.01 |
90.2 |
90.50 |
11,162,288 |
996,631 |
| IPO/Capital Increase against Cash |
30.06.00 |
125.4 |
42.00 |
10,100,000 |
2,985,354 |
